Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

The immune landscape of esophageal cancer.

Huang TX, Fu L.

Cancer Commun (Lond). 2019 Nov 26;39(1):79. doi: 10.1186/s40880-019-0427-z. Review.

2.

Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissue.

Sen M, Hahn F, Black TA, DeMarshall M, Porter W, Snowden E, Yee SS, Tong F, Ferguson M, Fleshman EN, Nakagawa H, Falk GW, Ginsberg GG, Kochman ML, Blaesius R, Rustgi AK, Carpenter EL.

Oncotarget. 2019 Jun 4;10(38):3592-3604. doi: 10.18632/oncotarget.26911. eCollection 2019 Jun 4. Erratum in: Oncotarget. 2019 Aug 20;10(49):5119.

3.

[Epidemiology of microsatellite instability across solid neoplasms].

Colle R, Cohen R.

Bull Cancer. 2019 Feb;106(2):114-118. doi: 10.1016/j.bulcan.2018.07.019. Epub 2018 Nov 5. Review. French.

PMID:
30409467
4.

The evolving immunotherapeutic landscape in advanced oesophagogastric cancer.

Flynn M, Young K, Cunningham D, Starling N.

Ther Adv Med Oncol. 2018 Jul 11;10:1758835918786228. doi: 10.1177/1758835918786228. eCollection 2018. Review.

5.

Systemic therapy for esophagogastric cancer: immune checkpoint inhibition.

Lyons TG, Ku GY.

Chin Clin Oncol. 2017 Oct;6(5):53. doi: 10.21037/cco.2017.09.03.

6.

The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.

Kelly RJ, Zaidi AH, Smith MA, Omstead AN, Kosovec JE, Matsui D, Martin SA, DiCarlo C, Werts ED, Silverman JF, Wang DH, Jobe BA.

Ann Surg. 2018 Dec;268(6):992-999. doi: 10.1097/SLA.0000000000002410.

PMID:
28806299
7.

Neoadjuvant Treatment for Locally Invasive Esophageal Cancer.

Iams WT, Villaflor VM.

World J Surg. 2017 Jul;41(7):1719-1725. doi: 10.1007/s00268-017-3959-x. Review.

PMID:
28271259
8.

Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.

Young K, Chau I.

Drugs. 2016 Jan;76(1):13-26. doi: 10.1007/s40265-015-0510-y. Review.

PMID:
26620367

Supplemental Content

Loading ...
Support Center